ADAP Form 8-K: Q2 Financial Results Announced, Exhibit 99.1 Furnished

Rhea-AI Filing Summary

Adaptimmune Therapeutics plc announced second-quarter financial results for the period ended June 30, 2025 and provided a corporate update. The Form 8-K furnishes the companys press release as Exhibit 99.1 and states that the furnished information is not deemed "filed" for purposes of Section 18 and is not incorporated by reference except by specific reference.

The filing does not include the financial figures or operational details; the full press release attached as Exhibit 99.1 contains the detailed results and corporate update.

Positive

• Company announced Q2 results for the period ended June 30, 2025 and provided a corporate update as stated in the filing.
• Press release furnished as Exhibit 99.1, making the corporate update and results available in a labeled exhibit.

Negative

• Filing does not include financial figures or operational detail in the body of the Form 8-K, so metrics are not available here.
• Information is "furnished" not "filed", which limits automatic incorporation by reference into other SEC filings.

Insights

Financial Analyst

TL;DR: Routine earnings disclosure furnished; no financial data included in the filing itself, limiting immediate assessment of performance.

The Form 8-K notifies investors that Adaptimmune announced second-quarter results for the period ended June 30, 2025 and furnished a press release as Exhibit 99.1. The company explicitly states the material is "furnished" and not "filed," which limits automatic incorporation into other SEC filings. Because this filing does not contain revenue, profit, cash flow, guidance or other quantitative metrics, the filing alone does not allow evaluation of operational or financial trends; the press release (Exhibit 99.1) must be reviewed for substantive metrics.

Corporate Governance Expert

TL;DR: Procedural 8-K furnishing a press release and clarifying legal status of the disclosure; appears to be standard corporate reporting practice.

The company furnished a press release and included a customary statement that furnished information is not "filed" under Section 18 and is not incorporated by reference except by specific reference. This language and the exhibit listing (including Exhibit 99.1 and the Inline XBRL cover page) are consistent with routine disclosure practices for earnings announcements and corporate updates. No governance issues, leadership changes, or material transactions are disclosed in this filing.

0001621227false00-000000000016212272025-08-132025-08-13

​

​

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 8-K

​

Current Report

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): August 13, 2025

​

ADAPTIMMUNE THERAPEUTICS PLC

(Exact name of registrant as specified in its charter)

​

​	​	​	​	​
England and Wales	​	1-37368	​	Not Applicable
(State or other jurisdiction of incorporation)	​	(Commission File Number)	​	(IRS Employer Identification No.)

​

60 Jubilee Avenue, Milton Park

Abingdon, Oxfordshire OX14 4RX

United Kingdom

(Address of principal executive offices, including zip code)

​

(44) 1235 430000

(Registrant’s telephone number, including area code)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class	​	Trading Symbol	​	Name of each exchange on which registered
American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share	​	ADAP	​	The Nasdaq Capital Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

​

​

​

​

​

​

Item 2.02    Results of Operations and Financial Conditions.

On August 13, 2025, Adaptimmune Therapeutics plc (the “Company”) announced its financial results for the second quarter ended June 30, 2025 and provided a corporate update. A copy of the press release is being furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

The information in Item 2.02 of this Current Report on Form 8-K, including the Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the "Exchange Act"), or incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by the Company by specific reference in such a filing.

Item 9.01    Financial Statements and Exhibits.

(d)  Exhibits.

Exhibit No.		Description of Exhibit
​	​	​
99.1	​	Press release dated August 13, 2025.
​	​	​
104	​	Cover Page Interactive Date File (embedded within the Inline XBRL document)

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

​	​
​	ADAPTIMMUNE THERAPEUTICS PLC
​	​	​
Date: August 13, 2025	By:	/s/ Margaret Henry
​	​	Name:	Margaret Henry
​	​	Title:	Corporate Secretary

​

​

FAQ

What did Adaptimmune (ADAP) disclose in this Form 8-K?

Adaptimmune announced second-quarter financial results for the period ended June 30, 2025 and provided a corporate update; the press release is furnished as Exhibit 99.1.

Does the Form 8-K include Q2 2025 financial figures for ADAP?

No. The Form 8-K states the press release is furnished as Exhibit 99.1 and the filing itself does not contain the financial figures or detailed results.

Where can I find the full press release referenced in the 8-K?

The press release is furnished as Exhibit 99.1 to the Form 8-K; review Exhibit 99.1 for the complete results and corporate update.

Is the furnished press release considered "filed" or incorporated by reference?

No. The company explicitly states the furnished information is not deemed "filed" for purposes of Section 18 and is not incorporated by reference except by specific reference in another filing.

What is Adaptimmunes ticker symbol and listing?

Adaptimmunes American Depositary Shares trade under the symbol ADAP on The Nasdaq Capital Market.